Safety/tolerability of the anti-semaphorin 4D antibody VX15/2503 in a randomized phase 1 trial
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received November 8, 2016
- Accepted in final form April 28, 2017
- First Published June 16, 2017.
Author Disclosures
- Christopher LaGanke, MD,
- Lawrence Samkoff, MD,
- Keith Edwards, MD,
- Lily Jung Henson, MD,
- Pavle Repovic, MD,
- Sharon Lynch, MD,
- Lael Stone, MD,
- David Mattson, MD,
- Aaron Galluzzi, MSc,
- Terrence L. Fisher, PhD,
- Christine Reilly, BS,
- Laurie A. Winter, BS,
- John E. Leonard, PhD and
- Maurice Zauderer, PhD
- Christopher LaGanke, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lawrence Samkoff, MD,
NONE
NONE
NONE
NONE
NONE
Samkoff, LM. and Goodman, AD (eds) (2014), Multiple Sclerosis and CNS Inflammatory Disorders, West Sussex, England: John Wiley & Sons, Ltd, 2014.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Keith Edwards, MD,
NONE
NONE
(1) Biogen, travel reimbursement for speaker (2) Genzyme, travel reimbursement for speaker (3) Novartis, travel reimbursement for speaker Resigned from all speaker talks as of June 2016
NONE
NONE
NONE
MS Center of Northeastern NY, Director, 2007-current
(1) Biogen (2) Genzyme (3) EMD Serono (4) Novartis Resigned from all consultancies as of June 2016
(1) Biogen (2) Genzyme (3) Novartis Resigned from all speaker bureaus as of June 2016
NONE
NONE
(1) Actelion (2) Biogen (3) Envivo Pharmaceuticals (4) Eisai Inc (5) Genentech (6) Genzyme (7) Hoffman-La Roche (8) Novartis (9) Pfizer (10) Vaccinex
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lily Jung Henson, MD,
1. Genzyme
NONE
1. Genzyme (travel/honoraria)
NONE
NONE
NONE
Piedmont, Chief of Neurology, 1 year (2015-2016) Piedmont, Chief Medical Officer, 1year (2015-present) Swedish Health Services, neurologist, 11 years (2004-2015) Swedish Health Services, VPMA, 1 year (2014-2015)
Biomarin Mitsubishi Tanabe
Genzyme Novartis Teva Pfizer Serono
NONE
NONE
Genzyme Biogen Novartis Opexa Parexel (spouse)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Merck (stock, > 25 years) Amgen (stock, 1 year)
expert witness for both defense and plaintiff (do not have list of firms)
- Pavle Repovic, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen, (2) sanofi genzyme, (3) Teva, (4) EMD Serono, (5) Novartis, (6) Anvil biosciences
(1) Biogen, (2) sanofi genzyme, (3) Teva, (4) EMD Serono, (5) Novartis, (6) Pfizer, (7) Acorda
NONE
NONE
(1) Novartis
(1) NIH #NS077309 co-principal investigator, 2014-present
NONE
(1) Guthy-Jackson Charitable Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Sharon Lynch, MD,
NONE
NONE
MS-CURE Non-profit, speaker Honorarium
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Novartis, Alexion, Acorda, Actelion, biogen, Sanofi, roche, Genentech, Chugai, Medimmune, Vaccinex, Sun Pharma, Teva,Genzyme, MedDay, Opexa
NIH- NN102 Investigator, 2013-2017
NONE
National Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
NONE
- Lael Stone, MD,
NONE
NONE
NONE
Editor in Chief, International Journal Of MS Care, 2008- ongoing
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
National Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
NONE
- David Mattson, MD,
Acorda Therapeutics, Biogen
NONE
Teva Neuroscience, speaker honoraria; Biogen, speaker honoraria, travel; EMD-Serono, speaker honoraria, travel; Pfizer, speaker honoraria, travel; Acorda Therapeutics, speaker honoraria, travel; Novartis, speaker honoraria, travel; Genzyme, speaker honoraria, travel; Bayer, speaker honoraria; Questcorp, speaker honoraria
NONE
NONE
NONE
NONE
NONE
Teva Neuroscience, Biogen-Idec, EMD-Serono, Pfizer, Acorda Therapeutics, Novartis, Genzyme, Bayer, Questcorp
NONE
NONE
Teva Neuroscience, Biogen , MedImmune, Roche, ONO, Acorda Therapeutics, Genentech, Novartis, Genzyme, Sanofi- Aventis, Actelion, Vaccinex, Alkermes
Indiana Clinical Translational Science Institute/NIH, TL1 TR000162, Co-PI, 5/1/2008-4/30/2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Aaron Galluzzi, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
Premier Research, Principal Biostatistician, 2016-present Chiltern International, Senior Biostatistician, 2015-2016 PRA Health Sciences, Senior Biostatistician, 2014-2015
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Terrence L. Fisher, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christine Reilly, BS,
NONE
NONE
NONE
NONE
NONE
NONE
1)Vaccinex Inc, Senior Research Scientist, 13yrs
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Laurie A. Winter, BS,
NONE
NONE
NONE
NONE
NONE
NONE
Current:Senior ScientistOrtho Clinical DiagnosticsEmployed Since May 2016-presentCurrent position/work is not associated with this manuscript. The work associated with this manuscript was from my tenure with Vaccinex prior to May 2016.
NONE
NONE
NONE
NONE
Ortho Clinical Diagnostics (May 2016-present) in the form of employment compensation.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- John E. Leonard, PhD and
NONE
NONE
NONE
NONE
Anderson, D.R., Hanna, N., Leonard, J.E., Newman, R.A. andReff, M.E. Therapeutic application of chimeric antibodyto human B lymphocyte restricted differentiation antigenfor treatment of B cell lymphoma. Filed November 13,1992, U.S. Patent and Trademark Office.Anderson, D.R., Leonard, J.E., Newman, R.A., Reff, M.E,and Rastetter, W.H. Therapeutic Application of Chimericand Radiolabeled Antibodies to Human B LymphocyteRestricted Differentiation Antigen for Treatment of B CellLymphoma, December 1, 1998, U.S. Patent and TrademarkOffice, Patent No. 5,843,439.Anderson, D.R.., Hanna, N., Leonard, J.E., Newman, R.A.,Reff, M.E, and Rastetter, W.H. Therapeutic Applicationsof Chimeric and Radiolabeled Antibodies to Human BLymphocyte Restricted Differentiation Antigen forTreatment of B Cell Lymphoma, January 27, 2004, U.S.Patent and Trademark Office, Patent No. 6,682,734.Anderson, D.R.., Hanna, N., Leonard, J.E., Newman, R.A.,Rastetter, W.H and, Reff, M.E, Chimeric Anti-CD20Antibody, October 13, 2008, European Patent Office, PatentNo., 08012898.5 ? 2404.Anderson, D.R., D.R., Hanna, N., Leonard, J.E., Newman,R.A., Reff, M.E, and Rastetter, W.H. Expression and Useof Anti-CD20 Antibodies, June 29, 2010, U.S. Patent andTrademark Office, Patent No. 7,744,877 B2.Leonard, JE, et al, Use of Chimeric Anti-CD20 Antibody asIn Vitro or In Vivo Purging Agent in Patients ReceivingBone Marrow Transplantation or Peripheral Blood Stem CellTransplant; June 10, 2013, U.S. Patent and TrademarkOffice, Patent No. 13/914,421.
NONE
Vaccinex, IncSenior Vice President, Development2009 to Present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Vaccinex, Inc2009 to Present
NONE
NONE
- Maurice Zauderer, PhD
NONE
NONE
NONE
NONE
1. Use of anti-semaphorin 4D antibody to treat cancer 2. Use of anti-semaphorin 4D antibody to treat neuroinflammatory/neurodegenerative diseases
NONE
Vaccinex, Inc., Chief Executive Officer & President, 19 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Vaccinex, Inc. 1998 to present
NONE
NONE
- Correspondence to Dr. Leonard: jleonard{at}vaccinex.com
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Articles
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MSD. H. Miller, D. Soon, K. T. Fernando et al.Neurology, April 23, 2007 -
Articles
Randomized multicenter trial of natalizumab in acute MS relapsesClinical and MRI effectsP. W. O’Connor, A. Goodman, A. J. Willmer-Hulme et al.Neurology, June 07, 2004 -
Article
Oral contraceptives combined with interferon β in multiple sclerosisCarlo Pozzilli, Laura De Giglio, Valeria T. Barletta et al.Neurology - Neuroimmunology Neuroinflammation, June 18, 2015 -
Articles
Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosisG. L. Mancardi, F. Sardanelli, R. C. Parodi et al.Neurology, April 01, 1998